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Background: Vitamin K has been related to glucose metabolism, insulin sensitivity and diabetes. Because
inflammation underlies all these metabolic conditions, it is plausible that the potential role of vitamin K in glucose
metabolism occurs through the modulation of cytokines and related molecules. The purpose of the study was to
assess the associations between dietary intake of vitamin K and peripheral adipokines and other metabolic risk
markers related to insulin resistance and type 2 diabetes mellitus.
Methods: Cross-sectional and longitudinal assessments of these associations in 510 elderly participants recruited in
the PREDIMED centers of Reus and Barcelona (Spain). We determined 1-year changes in dietary phylloquinone
intake estimated by food frequency questionnaires, serum inflammatory cytokines and other metabolic risk markers.
Results: In the cross-sectional analysis at baseline no significant associations were found between dietary
phylloquinone intake and the rest of metabolic risk markers evaluated, with exception of a negative association
with plasminogen activator inhibitor-1. After 1-year of follow-up, subjects in the upper tertile of changes in dietary
phylloquinone intake showed a greater reduction in ghrelin (−15.0%), glucose-dependent insulinotropic peptide
(−12.9%), glucagon-like peptide-1 (−17.6%), IL-6 (−27.9%), leptin (−10.3%), TNF (−26.9%) and visfatin (−24.9%) plasma
concentrations than those in the lowest tertile (all p<0.05).
Conclusion: These results show that dietary phylloquinone intake is associated with an improvement of cytokines
and other markers related to insulin resistance and diabetes, thus extending the potential protection by dietary
phylloquinone on chronic inflammatory diseases.
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Vitamin K (K1 or phylloquinone and K2 or menaquinones)
is recognized as an essential element in the synthesis of
carboxylate clotting factors involved in prothrombotic dis-
orders and cardiovascular disease. More recently, it has
been reported that vitamin K also participates in the
gamma-carboxylation reactions of other proteins such as
osteocalcin, and may also exert a protective role against
age-related bone loss [1,2]. However, additional roles of
vitamin K, independent of these effects have been described
[3]. Thus, there is evidence that both osteocalcin and vita-
min K may have a potential beneficial role in glucose me-
tabolism, insulin sensitivity and type 2 diabetes (T2DMs)
[4-7]. Since inflammation underlies all these chronic meta-
bolic conditions, it is plausible that the potential role of
vitamin K in glucose metabolism partly occurs through the
modulation of cytokines and other metabolic risk markers
related to insulin resistance and diabetes.
In-vitro studies have shown an anti-inflammatory effect
of vitamin K. Human macrophage THP-1 cells incubated
with vitamin K reduced the interleukin-6 (IL-6) expression
compared to non-incubated cells. Likewise, rats fed with a
vitamin K-deficient diet showed an enhanced expression
of genes involved in the acute inflammatory response [8].
In a subsample of 1,321 subjects from the Framingham
Offspring Study, both plasma phylloquinone and dietary
phylloquinone intake were inversely associated with per-
ipheral concentrations of some inflammatory markers [9].
However, in a 3-year randomized clinical trial designed to
assess the effect of vitamin K supplementation on bone
loss, no differences were found in the plasma IL-6, C-
reactive protein or osteoprotegerin concentrations of parti-
cipants receiving or not a phylloquinone supplement [10].
The purposes of the present study were to assess the
cross-sectional associations between dietary intake of
vitamin K1 and selected adipokines or other metabolic
risk markers related to inflammation, insulin resistance
and diabetes; and to longitudinally analyse the associa-
tions between changes in dietary phylloquinone intake
and changes in these risk markers after one-year of




In the present study we conducted a cross-sectional and
a longitudinal assessment of 568 consecutively recruited
participants for the PREDIMED trial centers of Reus and
Barcelona (Spain). The PREDIMED study is a large, pa-
rallel group, multicenter, controlled, randomized, clinical
trial designed to evaluate the effect of the Mediterranean
diet on the primary prevention of cardiovascular disease
in elderly. Participants were community-dwelling men
and women aged 55–80 and 60–80 years, respectively.At baseline they were free of cardiovascular disease and
were either diabetic or met at least three or more coro-
nary heart disease risk factors including smoking, hyper-
tension (blood pressure ≥ 140/90 mmHg or treatment
with antihypertensive drugs), dyslipidemia [low-density
lipoprotein cholesterol level ≥ 160 mg/dL or treatment
with hypolipidemic drugs], high-density lipoprotein
cholesterol level of 40 mg/dL or lower, overweight [Body
mass index ≥ 25 kg/m2] or family history of premature
cardiovascular disease. Exclusion criteria included any
severe chronic illness, drug or alcohol addiction, history
of allergy or intolerance to olive oil or nuts, or a low
predicted likelihood of changing dietary habits according
to Prochaska and DiClemente’s stages-of-change model.
The participants included in the PREDIMED study were
randomly assigned to 3 intervention groups: a Mediter-
ranean Diet with virgin olive oil, a Mediterranean Diet
with mixed nuts and a control group where a low-fat
diet is recommended according to the American Heart
Association guidelines. Full details of the PREDIMED
study protocol have been published elsewhere [11,12].
The study protocol was approved by the institutional re-
view boards of Hospital Clínic and Hospital Universitari
Sant Joan de Reus, and all subjects agreed to participate
in the study and gave their written informed consent.
The trail was registered in http://www.controlled-trials.
com as ISRCTN35739639.
Dietary assessment
Two individual motivational interviews every 3 months to
negotiate nutrition goals, and group educational sessions
on a quarterly basis, focused to adapt the customary diet
to a traditional Mediterranean diet, were compared with a
control group, which received verbal instructions and a
leaflet recommending the National Cholesterol Education
Program Adult Treatment Panel III dietary guidelines
(www.predimed.org). At baseline and after one-year of
follow-up participants were assessed by trained dieticians
who administered a previously validated 137-item food
frequency questionnaire (FFQ) [13]. Additionally, a vali-
dated brief 14-item Mediterranean Diet Adherence
Screener was used to assess adherence to the traditional
Mediterranean Diet (MedDiet) where subjects were asked
for their consumption of the most common Mediterra-
nean foods [14]. Subjects with a higher consumption of
healthier foods such as olive oil, vegetables, legumes, fruit,
nuts, fish and seafood, white meat instead of red meat,
sofrito and red wine scored higher in this questionnaire.
Energy and nutrient intakes were calculated from Spanish
food composition tables [15,16]. Dietary phylloquinone
intake was calculated using the database of the US Depart-
ment of Agriculture, Human Nutrition Research Center
on Aging at Tufts University (http://www.nal.usda.gov/
fnic/foodcomp/search) and the reproducibility and relative
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validated for dietary phylloquinone intake. Reproducibility
for dietary phylloquinone intake explored by the Pearson
correlation coefficient (r) ranged was 0.755, and the intra-
class correlation coefficient (ICC) was 0.860, p<0.001.Other measurements
Additional information was collected on subjects’ me-
dical record, including the use of medication. Trained
personnel measured baseline weight, height and waist
circumference as previously reported [11,12], as well as
blood pressure in triplicate with a validated semiauto-
matic oscillometer (Omron HEM-705CP, Hoofddorp,
the Netherlands). Leisure-time physical activity was
evaluated using the validated Spanish version of the
Minnesota leisure-time physical activity questionnaire.
Centralized laboratory biochemical analyses were per-
formed on blood samples obtained in fasting conditions.
Plasma glucose, serum cholesterol, high-density lipo-
protein cholesterol and triglyceride concentrations were
determined using standard enzymatic automated me-
thods. In patients whose triglyceride levels were less
than 400 mg/dL, low-density lipoprotein cholesterol
concentrations were estimated using the Friedewald
formula. Inflammatory and metabolic markers (adiponec-
tin, adipsin, C-peptide, ghrelin, glucagon-like peptide-1
(GLP-1), glucose-dependent insulinotropic polypeptide,
IL-6, leptin, plasminogen activator inhibitor-1 (PAI-1),
resistin, tumor necrosis factor (TNF) and visfatin were
determined in plasma using the Bio-Plex cytokine assay
(Bio-Rad Laboratories Inc., Hercules, CA, USA) according
to manufacturer’s instructions.Statistical analysis
Mean (SD) or percentages (%) were used to describe the
participant’s baseline characteristics. Inflammatory
and metabolic risk markers of insulin resistance and
diabetes were logarithmically transformed to achieve a
normal distribution, and the geometric mean and
95% confidence interval were used to describe these
variables. For cross-sectional associations, we used mul-
tivariable linear regression models to assess the associa-
tions between metabolic risk markers (dependent
variables in each model) and dietary vitamin K intake
(independent variable in all models) adjusted for poten-
tial confounding variables [age, sex, body mass index,
smoking (never, current, past), physical activity (kcal/d),
type 2 diabetes mellitus (T2DM), total energy (kcal/d)
and fibre intake (g/d), dietary polyunsaturated fatty
acids (PUFA) intake (g/d) and adherence to MedDiet
(14-item score, quantitative)]. The selection of potential
confounders was done using clinical plausible and bib-
liographical criteria.Interaction tests for sex and T2DM (sex*vitamin K
intake, T2DM* vitamin K intake) were not statistically
significant. No interaction was observed for intervention
group and changes in dietary phylloquinone intake in
any outcome (inclusion of intervention group*one-year
changes in dietary phylloquinone intake in the regres-
sion models). In the longitudinal analyses, subjects were
categorized according to tertiles of changes in dietary
vitamin k intake from baseline to 1-year follow-up. A
multivariable linear regression model was fitted to evalu-
ate the relationship between metabolic risk markers at
1-year of follow-up (dependent variables in each model)
and tertiles of change in vitamin k intake (independent
variable in all models) adjusting by age, sex, smoking
(never, current, past), physical activity (kcal/d), T2DM,
intervention group, baseline values of each metabolic
marker and changes in BMI, total energy intake (kcal/d),
fiber intake (g/d), dietary PUFA intake (g/d) and adher-
ence to MedDiet (the relative change in the 14-item
score was expressed as a percentage). All statistical tests
were two-tailed, and the significance level was p<0.05.
Statistical analysis was performed using SPSS 17.0 for
Windows (SPSS Inc, Chicago, IL).
Results
Of the 568 subjects consecutively recruited, 57 were
excluded because they were using anti-inflammatory
medication at baseline and 1 because he hd not com-
pleted the FFQ at follow-up. Table 1 summarizes the
baseline characteristics of the study participants. Study
subjects were 67.2±6.0 years old and 44.4% of them were
male. Most of them were overweight or obese (92.2%),
had hypertension (91.8%), were hypercholesterolemic
(62.9%), and 55% had T2DM. Table 2 presents the base-
line and 1-year dietary changes by tertiles of change in
dietary phylloquinone intake. Subjects in the highest ter-
tile of change consumed less amounts of vitamin K1 at
baseline. This change after intervention was due to a
higher consumption of total vegetables and, especially,
leafy green vegetables, the primary dietary source of vita-
min K1. In cross-sectional analyses at baseline, a nega-
tive significant association was found between dietary
phylloquinone intake and PAI-1 plasma concentrations,
even after adjusting for potential confounders (Table 3),
but not for the rest of the metabolic risk markers. How-
ever, after 1-year of follow-up, those subjects in the
upper tertile of changes in dietary phylloquinone intake
showed a significant greater reduction in ghrelin
(15.0%), GIP (12.9%), GLP-1 (17.6%), IL-6 (27.9%), leptin
(10.3%), TNF (26.9%) and visfatin (24.9%) than those
subjects in the lowest tertile (Table 4). No significant
associations were found between changes in dietary
phylloquinone intake and other metabolic markers of in-
flammation, insulin resistance and diabetes.
Table 1 Baseline characteristics of study subjects by tertiles of change in dietary phylloquinone intake (μg/day)
Characteristics All subjects (n=510) P
Tertile 1 Tertile 2 Tertile 3
(−718.2 to −69.9) (−26.8 to 69.4) (70.5 to 767.5)
Clinical characteristics
Men/women, n 80/92 68/107 78/85 0.194
Age, years 66.8 ± 6.1 68.1 ± 6.2 66.6 ± 5.7 0.030
BMI, kg/m2 29.39 ± 3.17 29.21 ± 3.18 29.17 ± 3.05 0.608
Waist circumference, cm 100.6 ± 8.6 100.5 ± 9.2 100.9 ± 8.9 0.940
Current smoker, n (%) 26 (15.1) 29 (16.6) 16 (9.8) 0.561
Type 2 diabetes, n (%), 95 (55.2) 100 (57.1) 85 (52.1) 0.650
Overweight/Obesity, n (%) 159 (92.4) 162 (92.6) 149 (91.4) 0.911
Hypertension, n (%) 156 (90.7) 164 (93.7) 148 (90.8) 0.121
Dyslipydemia, n (%) 103 (61.7) 116 (68.6) 92 (57.9) 0.511
Intervention group MD+VOO/MD+nuts/CD, n 44/54/74 64/57/54 76/45/42 0.001
Leisure-time physical activity, METS-min/day 277.8 ± 261.9 263.0 ± 247.8 294.2 ± 279.4 0.313
Metabolic risk markers
C-Peptide (ng/mL) 1.41 (1.34 to 1.49) 1.33 (1.24 to 1.44) 1.34 (1.25 to 1.42) 0.374
Ghrelin (pg/mL) 12.88 (11.95 to 3.89) 13.38 (12.31 to 14.54) 12.77 (11.75 to 13.87) 0.685
GIP (pg/mL) 92.55 (84.76 to 101.05) 98.40 (89.70 to 107.95) 85.72 (78.25 to 93.91) 0.107
GLP-1 (ng/mL) 1.22 (1.09 to 1.36) 1.31 (1.17 to 1.48) 1.16 (1.03 to 1.30) 0.312
IL-6 (pg/ml) 9.96 (8.80 to 11.27) 10.88 (9.63 to 12.29) 8.99 (7.93 to 10.19) 0.102
Leptin (ng/mL) 2.87 (2.60 to 3.17) 3.20 (2.88 to 3.57) 2.91 (2.63 to 3.22) 0.262
PAI-1 (ng/mL) 3.20 (3.05 to 3.37) 3.28 (3.11 to 3.46) 3.37 (3.21 to 3.54) 0.378
Resistin (ng/mL) 0.98 (0.92 to 1.05) 1.05 (0.98 to 1.12) 1.01 (0.94 to 1.08) 0.413
TNF (pg/mL) 13.36 (11.57 to 15.44) 13.76 (11.89 to 15.93) 11.35 (9.80 to 13.14) 0.145
Visfatin (ng/mL) 4.13 (3.53 to 4.84) 4.54 (3.85 to 5.37) 3.70 (3.13 to 4.37) 0.225
Adiponectin (μg/mL) 48.87 (42.67 to 55.98) 49.51 (42.68 to 57.43) 42.37 (35.45 to 50.64) 0.302
Adipsin (μg/mL) 1.12 (1.01 to 1.24) 1.14 (1.03 to 1.28) 0.91 (0.77 to 1.08) 0.029
Data are given as mean (SD) or number (%) unless otherwise indicated. Metabolic risk markers are expressed as geometric means (IC95%). P values of the
difference between tertils of change in dietary phylloquinone intake (ANOVA for the continuous variables and a χ2 test for categorical variables). MD+VOO
Mediterranean diet + Virgin Olive Oil, MD+nuts Mediterranean diet + Nuts, CD Control diet, BMI body mass index, GLP-1 glucagon-like peptide 1,
GIP glucose-dependent insulinotropic polypeptide; IL-6 interleukin-6, PAI-1 plasminogen activator inhibitor-1, TNF-α tumor necrosis factor-α.
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The results of this study show, for the first time, that an
increased dietary intake of phylloquinone is associated
with an improvement in inflammatory and other meta-
bolic risk markers related to insulin resistance and dia-
betes, thus supporting a protective role of vitamin K on
low-grade chronic inflammatory diseases.
In recent years, vitamin K has been attributed a puta-
tive role in glucose metabolism, insulin resistance and
T2DM [17]. Recently, in a prospective study our group
has shown that a higher dietary phylloquinone intake
was associated to a lower risk of developing T2DM.
However, the exact mechanisms underlying this relation-
ship remain still unknown. One potential explanatory
mechanism could be related to the role of vitamin K as
a cofactor in the carboxylation of vitamin K-dependent
proteins, such as osteocalcin [18], GAS6 or Protein S
[19] and through their role on NF-kB [20-22].Additionally, some authors have suggested that inflam-
mation may be modulated by a possible antioxidant ef-
fect of vitamin K [23].
A cross-sectional study conducted in a subsample
from the Framingham Offspring Study, showed an in-
verse association between 2-fold changes in usual dietary
phylloquinone intake or plasma phylloquinone concen-
trations and seven of the fourteen peripheral inflamma-
tory markers measured [9]. However, the same authors,
in a cross-sectional analysis conducted on 400 healthy
elderly men and women, did not find any significant as-
sociation between plasma phylloquinone concentrations
and C-reactive protein or IL-6 after adjusting for poten-
tial confounders [10]. Similar to the results from Shea
and co-workers, we also failed to find any significant as-
sociation between dietary phylloquinone intake and most
of the metabolic risk markers analysed. However, our
longitudinal findings are generally consistent with in-
Table 2 Baseline and 1-year change of dietary characteristics by tertiles of change in dietary phylloquinone
intake (μg/day)
Tertile 1 Tertile 2 Tertile 3 P
(n=172) (n=175) (n=163)
Total energy intake, (kcal/d)
Baseline 2526 ± 557 2359 ± 547 2270 ± 514 <0.001
Change −85 ± 561 86 ± 30 198 ± 521 <0.001
Energy from total protein, (% kcal)
Baseline 17 ± 3 17 ± 3 17 ± 3 0.386
Change 0 ± 3 −1 ± 3 0 ± 3 0.134
Energy from total carbohidrates, (% kcal)
Baseline 42 ± 6 42 ± 7 42 ± 7 0.982
Change −2 ± 6 −2 ± 7 −2 ± 8 0.958
Fiber intake, g/1,000 kcal
Baseline 12 ± 4 12 ± 3 11 ± 3 0.023
Change −1 ± 3 0 ± 2 2 ± 3 <0.001
Energy from total fat, (% kcal)
Baseline 39 ± 6 39 ± 6 39 ± 6 0.393
Change 2 ± 6 3 ± 7 2 ± 8 0.240
Saturated fatty acids, (%)
Baseline 27 ± 4 26 ± 5 26 ± 4 0.829
Change −2 ± 5 −3 ± 5 −2 ± 5 0.271
MUFA, (%)
Baseline 49 ± 5 48 ± 5 49 ± 5 0.242
Change 1 ± 6 2 ± 5 1 ± 6 0.140
PUFA, (%)
Baseline 17 ± 4 17 ± 4 16 ± 4 0.456
Change 0 ± 5 1 ± 5 1 ± 5 0.221
Phylloquinone intake, (μg/d)
Baseline 490 ± 229 401 ± 209 297 ± 163 <0.001
Change −176 ± 150 16 ± 25 266 ± 164 <0.001
Vegetable consumption, (g/d)
Baseline 413 ± 167 380 ± 182 335 ± 186 <0.001
Change −42 ± 180 17 ± 131 141 ± 175 <0.001
Leafy green vegetables, (g/d)
Baseline 112 ± 47 95 ± 47 75 ± 44 <0.001
Change −30 ± 38 1 ± 20 55 ± 44 <0.001
Other vegetables, (g/d)
Baseline 276 ± 138 265 ± 142 239 ± 147 0.053
Change −13 ± 149 7 ± 120 79 ± 153 <0.001
Fruit consumption, (g/d)
Baseline 479 ± 258 451 ± 240 432 ± 251 0.221
Change −12 ± 223 36 ± 211 67 ± 238 0.005
Legume consumption, (g/d)
Baseline 20 ± 11 19 ± 12 17 ± 9 0.046
Change 1 ± 12 4 ± 12 7 ± 13 <0.001
Cereal consumption, (g/d)
Baseline 270 ± 103 256 ± 102 249 ± 103 0.150
Change −27 ± 100 −10 ± 119 −1 ± 113 0.091
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Table 2 Baseline and 1-year change of dietary characteristics by tertiles of change in dietary phylloquinone
intake (μg/day) (Continued)
Dairy product consumption, (g/d)
Baseline 357 ± 227 371 ± 252 349 ± 195 0.656
Change −8 ± 212 −8 ± 190 2 ± 181 0.854
Meat consumption, (g/d)
Baseline 154 ± 61 148 ± 61 143 ± 56 0.243
Change −14 ± 58 −12 ± 62 −2 ± 61 0.137
Fish consumption, (g/d)
Baseline 115 ± 46 106 ± 46 106 ± 42 0.099
Change −1 ± 52 9 ± 46 15 ± 43 0.008
Alcohol intake, (g/d)
Baseline 13 ± 19 10 ± 19 7 ± 12 0.013
Change 0 ± 13 −1 ± 17 1 ± 9 0.173
Olive oil consumption, (g/d)
Baseline 39 ± 15 36 ± 14 38 ± 15 0.248
Change 5 ± 19 11 ± 19 9 ± 20 0.021
Nut consumption, (g/d)
Baseline 16 ± 17 14 ± 15 11 ± 13 0.029
Change 7 ± 25 10 ± 25 11 ± 24 0.185
14-item PREDIMED MedDiet Score
Baseline 9 ± 2 9 ± 2 8 ± 2 0.443
Change 1 ± 2 1 ± 2 2 ± 2 0.031
Data expressed as mean ± standard deviation. ANOVA was used for analysis of the difference between tertils of change in vitamin K intake. Abbreviations: MUFA
monounsaturated fatty acids, PUFA polyunsaturated fatty acids, MedDiet Mediterranean diet.
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study. In-vitro studies found that the production of the
proinflammatory cytokines IL-6 or TNF by human gin-
gival fibroblast or mouse macrophage cells, respectively,
decreased when cells were incubated with different vita-
min K family compounds [21,24]. Other studies have
found that vitamin K suppresses inflammation by lower-
ing the expression of genes for some proinflammatory
cytokines, such as IL-6, IL-1β and TNF [8,22]. However,
only a single 3-year, double-blind, randomized controlled
trial has been conducted to evaluate the effect of vitamin
K supplementation on peripheral inflammatory marker
concentrations. In that study, conducted with 379
healthy men and women, no significant relationship be-
tween plasma phylloquinone levels and inflammation
markers was shown [10]. In our study we observed a
significant improvement in the inflammatory status
(leptin, IL-6, TNF) and a decrease in other metabolic
risk markers related to insulin resistance and diabetes
such as visfatin, ghrelin, GIP and GLP-1 among subjects
who increased their dietary intake of phylloquinone
after 1-year follow-up, thus contributing to extend the
knowledge on the role of vitamin K in humans and to
support our previous results on dietary phylloquinone
intake and T2DM incidence [7]. The discrepancies be-
tween our results and those previously published couldbe partly explained by the differences between the
populations. Our participants were elderly subjects at
high cardiovascular risk, whereas, subjects in the study
of Shea [9] were healthy and generally free of chronic
disease. This may contribute to explain why inflamma-
tory cytokines remained unchanged in that study.
Moreover, in our study we assessed the association of
inflammation with dietary phylloquinone intake instead
of plasma phylloquinone as was done in the previous
study. Whether circulating levels of phylloquinone are
correlated to dietary phylloquinone intake remains to
be elucidated.
It must be noted that leptin, IL6 and TNF are pro-
inflammatory cytokines with a recognised role in the de-
velopment and progression of insulin resistance, T2DM
and cardiovascular disease [25,26]. Also visfatin and
ghrelin appears as important mediators of inflammation
in addition to glucose-lowering and insulin-mimicking/
sensitizing effects or a suppressive role of ghrelin in the
release of insulin from the pancreatic islets [27-30]. A
strong inverse correlation between plasma ghrelin con-
centrations and insulin resistance has been observed in
several studies [30-32] and lower concentrations of ghre-
lin have been observed in T2DM subjects [33]. The
negative relationship between changes in dietary phyllo-
quinone intake and plasma incretin concentrations
Table 3 Cross-sectional associations between intake of 100 μg of dietary phylloquinone and inflammatory or
metabolic markers at baseline
Change in inflammatory marker for 100 additional μg of dietary phylloquinone intake
(95% confidence intervals)
P
C-Peptide (ng/mL) −0.73 (−2.68 to 1.27) 0.472
Ghrelin (pg/mL) −1.25 (−3.76 to 1.33) 0.339
GIP (pg/mL) −0.13 (−2.98 to 2.80) 0.928
GLP-1 (ng/mL) −1.81 (−5.40 to 1.91) 0.335
IL-6 (pg/ml) −1.68 (−5.46 to 2.25) 0.396
Leptin (ng/mL) −1.48 (−3.80 to 0.90) 0.221
PAI-1 (ng/mL) −1.64 (−3.23 to −0.0)2 0.047
Resistin (ng/mL) −1.42 (−3.61 to 0.81) 0.210
TNF (pg/mL) −1.24 (−5.73 to 3.46) 0.598
Visfatin (ng/mL) −1.42 (−6.54 to 3.98) 0.599
Adiponectin (μg/mL) 2.45 (−2.23 to 7.35) 0.310
Adipsin (μg/mL) 1.21 (−2.84 to 5.43) 0.563
Multivariable linear regression models were used for analysis. Data are given in % of change (95% IC). Models are adjusted for sex, age, body-mass-index, smoking
(never, current, past), total energy intake (kcal/d), dietary fibre intake (g/d), dietary polyunsaturated fatty acids intake (g/d), physical activity (kcal/d), Mediterranean
Diet Score (14-item PREDIMED score, quantitative), and T2DM. GIP Gastric inhibitory polypeptide, GLP-1 Glucagon-like peptide-1, IL-6 Interleukin-6, PAI-1
Plasminogen activator inhibitor-1, TNF Tumor Necrosis Factor α.
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higher intake of phylloquinone may promote better
glycemic control thus leading less necessary the glucose
and insulin regulation mediated by incretins. However,
the pleiotropic role recently attributed to incretins could
also contribute to explain our results. Although there is
growing evidence that incretin hormones (GIP and
GLP-1) simulate glucose-dependent insulin secretion
and stimulate pancreatic synthesis of insulin, a novel link
between inflammation and incretin hormones has been
proposed. First, IL-6 increase GLP-1 production in intes-
tinal L cells and alpha pancreatic cells improving insulin
secretion and glycemia [34]. Therefore, the reduction ofTable 4 Longitudinal associations between one-year changes
change in dietary phylloquinone intake (μg/day)
Tertile 1 Tertile 2
C-Peptide (ng/mL) Ref. −2.19 (−8.35 to 4.40)
Ghrelin (pg/mL) Ref. 1.69 (−8.58 to 13.11)
GIP (pg/mL) Ref. 0.08 (−10.17 to 11.49)
GLP-1 (ng/mL) Ref. 0.21 (−12.99 to 15.42)
IL-6 (pg/ml) Ref. −4.50 (−18.17 to 11.46)
Leptin (ng/mL) Ref. −7.79 (−15.61 to 0.76)
PAI-1 (ng/mL) Ref. −3.06 (−10.65 to 5.17)
Resistin (ng/mL) Ref. −2.43 (−11.03 to 7.01)
TNF (pg/mL) Ref. −3.96 (−20.47 to 15.98)
Visfatin (ng/mL) Ref. −8.08 (−24.73 to 12.24)
Adiponectin (μg/mL) Ref. −3.27 (−19.20 to 15.79)
Adipsin (μg/mL) Ref. −2.45 (−15.37 to 12.45)
Multivariable linear regression models were used for analysis. Data are given in % o
body-mass-index, smoking (never, current, past), change of total energy intake (kca
intake (g/d), physical activity (kcal/d), intervention group, change of Mediterranean
GIP Gastric inhibitory polypeptide, GLP-1 Glucagon-like peptide-1, IL-6 Interleukin-6,IL-6 levels observed in the subjects allocated in the high-
est tertile of change in phylloquinone intake could partly
explain the reduction in GLP-1 concentrations in this
group. Nie et al., have also demonstrated the capacity of
GIP to activate inflammatory response and promote se-
cretion of pro-inflammatory cytokines and chemokines
in cell culture adipocytes [35]. Additionally, a potential
role of GIP on adipose tissue insulin resistance mediated
by osteopontin regulation has also been suggested [36].
The results from our study could be related to the po-
tential role of incretins on adipose tissue in a fasting
situation rather than to their established role on pancre-
atic cells in a post-prandial state. Whether or not GIPin inflammatory or metabolic markers and tertiles of
p Tertile 3 p p for trend
0.505 −6.10 (−12.61 to 0.91) 0.086 0.083
0.758 −15.00 (−24.49 to −4.32) 0.007 0.003
0.989 −12.94 (−22.75 to −1.89) 0.023 0.014
0.977 −17.64 (−29.67 to −3.56) 0.016 0.009
0.559 −27.89 (−39.20 to −14.48) <0.001 <0.001
0.073 −10.26 (−18.62 to −1.03) 0.030 0.044
0.454 −3.24 (−11.61 to 5.93) 0.476 0.529
0.601 −6.66 (−15.71 to 3.35) 0.184 0.180
0.674 −26.89 (−40.65 to −9.94) 0.003 0.002
0.408 −24.90 (−39.86 to −6.22) 0.012 0.010
0.716 −7.34 (−23.98 to 12.93) 0.449 0.452
0.732 −7.39 (−20.90 to 8.44) 0.340 0.332
f change (95% IC). Models are adjusted for sex, age, change of
l/d), change of fibre intake (g/d), change of dietary polyunsaturated fatty acids
Diet Score (%), T2DM and baseline values of each metabolic marker.
PAI-1 Plasminogen activator inhibitor-1, TNF, Tumor Necrosis Factor α.
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related pro-inflammatory markers could not be eluci-
taded from the results of our study. Specific studies are
needed to get a deeper understanding of the exact role
of incretins on adipose tissue and their interaction with
the rest of adipokynes.
Our study has several limitations. It should be kept in
mind that the subjects in our study were randomly allo-
cated to a healthy Mediterranean diet that could partially
account for the reduction in peripheral metabolic risk
markers in some of them although no significant inter-
action between intervention group and dietary phyllo-
quinone intake was observed for any of the outcomes. In
order to minimize the potential effect of a healthy
dietary pattern on inflammatory response we have
adjusted the regression models for the adherence to a
MedDiet. Subjects in the PREDIMED study reported a
higher dietary intake of phylloquinone than in other
epidemiological studies, probably because this study was
conducted in a Mediterranean country where the con-
sumption of fruit and vegetables is high. In populations
with a lower consumption of phylloquinone or poor nu-
trition an increase in dietary vitamin K1 would probably
be much more beneficial. The cohort studied was elderly
and at high risk of cardiovascular disease, so our findings
cannot be generalized to younger or healthier indivi-
duals. Because there is no perfect correlation between
dietary phylloquinone intake and its absorption it would
be interesting in the future to evaluate the associations
showed in our study not only with dietary phylloquinone
intake but also with a circulating marker of vitamin K
status. Finally, we cannot discount a slight overesti-
mation of dietary phylloquinone intake due to the use of
FFQ and the USDA Food Database Composition. Al-
though the FFQ used in our study was not specifically
validated for phylloquinone intake, the intraclass correl-
ation coefficient of vegetables (the main source of diet-
ary vitamin K1) was 0.81, one of the highest coefficients
obtained during the validation of the FFQ in the PRE-
DIMED cohort [13]. Balanced against these limitations,
the main strength of our study is its longitudinal design,
which enables us to suggest a cause-effect relationship
between changes in dietary phylloquinone intake and
changes in inflammatory and related metabolic risk mar-
kers. In addition, our study was conducted in a large
sample of individuals, and measured a panel of adipo-
kines and related molecules involved in inflammation,
glucose metabolism and cardiovascular risk.
In summary, our results support that an increase in
dietary phylloquinone intake can lead to an improve-
ment in inflammation and inflammatory-related mole-
cules and also support the contention that high vitamin
K1 intake has a beneficial effect on cardiovascular
disease and other inflammation-related disorders.Abbreviations
FFQ: Food Frequency Questionnaire; GLP-1: Glucagon-like peptide 1;
IL: Interleukin; MedDiet: Mediterranean Diet; PAI-1: Plasminogen activator
inhibitor-1; T2DM: Type 2 diabetes mellitus; TNF: Tumor necrosis factor alpha.
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